ozanimod   Click here for help

GtoPdb Ligand ID: 8709

Synonyms: RPC-1063 | RPC1063 | Zeposia®
Approved drug PDB Ligand Immunopharmacology Ligand
ozanimod is an approved drug (EMA & FDA (2020))
Compound class: Synthetic organic
Comment: Ozanimod (RPC1063) is a novel, orally available, specific and potent agonist of the sphingosine 1-phosphate 1 receptor (S1P1R) and SIP5Rs [8]. Ozanimod is compound 86 in patent US20110172202 A1 [7], which specifies the (S)-enantiomer.
Ozanimod reduces chronic inflammation and alleviates kidney pathology in a mouse model of systemic lupus erythematosus (SLE), which suggests that ozanimod may offer clinical benefit as a SLE therapeutic [10].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 104.2
Molecular weight 404.18
XLogP 3.73
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES OCCNC1CCc2c1cccc2c1noc(n1)c1ccc(c(c1)C#N)OC(C)C
Isomeric SMILES OCCN[C@H]1CCc2c1cccc2c1noc(n1)c1ccc(c(c1)C#N)OC(C)C
InChI InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1
InChI Key XRVDGNKRPOAQTN-FQEVSTJZSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Ozanimod was progressed to Phase 3 clinical evaluation for its potential immunomodulating effects in relapsing multiple sclerosis (RMS) [5] and ulcerative colitis [1]. In late March 2020 the FDA approved ozanimod (0.92 mg) for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. EMA approval followed on May 20th of the same year.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
S1PR1 modulation selectively and reversibly promotes sequestration of circulating lymphocytes in peripheral lymphoid tissue by modulating lymphocyte trafficking. Importantly, this action inhibitis migration of autoreactive lymphocytes to areas of disease inflammation, which is a major contributor to autoimmune disease. S1PR1 modulation may also reduce lymphocyte migration into the central nervous system (CNS), where some indicated disease processes take place. This therapeutic approach downregulates the pathological effects of autoreactive lymphocytes which underly the autoimmune diseases being investigated in clinical trials of ozanimod, but may also be a useful strategy for other autoimmune conditions.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02047734 Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (Radiance Study) Phase 3 Interventional Celgene This clinical trial has been completed. Results showed superiority of oral ozanimod (significantly lower rate of clinical relapses) over intramuscularly delivered IFN-β1a (Avonex®). 3
NCT02294058 Phase 3 Study of RPC1063 in Relapsing MS Phase 3 Interventional Celgene Results from this trial, and the ozanimod vs. IFN-β1a trial NCT02047734 contributed to the FDA approval of ozanimod as an oral therapy for the treatment of relapsing forms of multiple sclerosis. 4